One year later: The case of tocilizumab in COVID-19.

Campochiaro, Corrado; Tomelleri, Alessandro; Matucci-Cerinic, Marco; Dagna, Lorenzo

Campochiaro, Corrado; Tomelleri, Alessandro; Matucci-Cerinic, Marco; Dagna, Lorenzo.

Campochiaro C; Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Hospital, Via Olgettina 60, Milan 20132, Italy; Vita-Salute San Raffaele University, Milan, Italy.
Tomelleri A; Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Hospital, Via Olgettina 60, Milan 20132, Italy; Vita-Salute San Raffaele University, Milan, Italy.
Matucci-Cerinic M; Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Hospital, Via Olgettina 60, Milan 20132, Italy; Department of Experimental and Clinical Medicine, and Division of Rheumatology AOUC, University of Florence, Florence, Italy.
Dagna L; Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Hospital, Via Olgettina 60, Milan 20132, Italy; Vita-Salute San Raffaele University, Milan, Italy. Electronic address: dagna.lorenzo@unisr.it.

Eur J Intern Med ; 95: 5-6, 2022 01.

Article in English | MEDLINE | ID: covidwho-1474499

Subject(s)

COVID-19 Drug Treatment; Antibodies, Monoclonal, Humanized; Humans; SARS-CoV-2

Keywords

COVID-19; Randomized-controlled trials; Tocilizumab; Treatment

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment Limits: Humans Language: English Journal: Eur J Intern Med Journal subject: Internal Medicine Year: 2022 Document Type: Article Affiliation country: J.ejim.2021.10.024

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google